The dual role of tetraspanin CD63 in HIV-1 replication
© Li et al.; licensee BioMed Central Ltd. 2014
Received: 23 October 2013
Accepted: 5 February 2014
Published: 8 February 2014
Skip to main content
© Li et al.; licensee BioMed Central Ltd. 2014
Received: 23 October 2013
Accepted: 5 February 2014
Published: 8 February 2014
Previously, we showed that the tetraspanin membrane protein CD63 mediates both early and post-integration stages of the HIV-1 replication cycle. The temporal roles of CD63 were discerned using monoclonal antibodies and small interfering RNAs (siRNAs) to block CD63 function, and determining which of the sequential steps in HIV-1 replication were disrupted. Inhibition was shown to occur during early infection, suggestive of involvement in virus entry or reverse transcription. In addition, we have shown that treatment with CD63 siRNA post-infection, significantly inhibited virus production in supernatant, suggesting an important role for CD63 in macrophages during HIV-1 replication events occurring after proviral integration, and possibly during egress.
In this study we used CD63 siRNA to investigate the infectivity of pseudotyped viruses (carrying an NL4-3 Env-negative luciferase backbone) in primary human macrophages. We demonstrated that lab adapted R5- and R5X4-tropic HIV-1 strains are significantly inhibited by CD63 silencing. However, the infectivity of MLV or VSV-pseudotyped strains, which enter though receptor-mediated endocytosis, is unaffected by silencing CD63. These results indicate that CD63 may support Env-mediated entry or fusion events facilitated though CD4 and CCR5. Also, antibody and siRNA-based CD63 inhibition studies indicate a potential role for CD63 following proviral integration. Further, we show that CD63 expression is key for efficient replication in primary CD4+ T cells, complementing our prior studies with primary human macrophages and immortalized cell lines.
Collectively, these findings indicate that CD63 may support Env-mediated fusion as well as a late (post-integration) step in the HIV-1 replication cycle.
Macrophages (MØ) and CD4+ T lymphocytes are target reservoirs for HIV-1 infection and replication, and play critical roles in multiple aspects of viral pathogenesis. HIV-1 relies on numerous host determinants for successful completion of each of the replicative steps of the viral life cycle from entry to egress [1–11].
CD63 is a type II cellular membrane protein belonging to the tetraspanin superfamily [12, 13]. CD63 associates with tetraspanin-enriched microdomains (TEMs), which have been shown to act as gateways for HIV-1 budding at the plasma membrane . Numerous studies have shown that CD63 readily incorporates into HIV-1 virions [15–17] and partially colocalizes with HIV-1 Env and Gag proteins in HIV-1 producing cells [16, 18–21]. Colocalization and virion incorporation data indirectly suggest a positive role for CD63 in the HIV-1 replication cycle, although this has not always been borne out experimentally, and conflicting results have been observed. For example, a recent study showed that CD63 suppresses trafficking of the chemokine receptor CXCR4 to the cell surface, which affects HIV-1 entry into T lymphocytes [22–24]. However, we have demonstrated that anti-CD63 monoclonal antibody or siRNA treatment does not affect the expression of the other major coreceptor CCR5, or the primary receptor CD4 [25–27]. Another recent paper showed CD63 is not required for HIV-1 infection of human MØ , in contrast with our prior studies.
Our laboratory and others have demonstrated that CD63 is important for HIV-1 replication in primary MØ and CD4+ cell lines [25–27, 29]. Our earlier studies showed that anti-CD63 monoclonal antibody treatment 30 min prior to and during infection markedly reduced HIV-1 replication in MØ . Inhibition was shown to occur during early infection, suggestive of involvement in virus entry or reverse transcription. Subsequently, we confirmed the requirement of CD63 in HIV-1 replication in primary human MØ and an immortalized CD4+ cell line following CD63 down regulation by siRNA [26, 27], and presently show its requirement by HIV-1 in primary human CD4+ T lymphocytes. Here, we show that CD63 expression supports Env-mediated fusion during MØ transduction with pseudotyped viruses. Down modulating CD63 expression in latently infected U1 cells blocked viral egress, but not intracellular p24 production, indicating CD63 also regulates a late replication step(s). Implications of our findings with regard to mechanisms of HIV-1 replication are discussed below.
Like human MØ, CD4+ T lymphocytes are also target reservoirs for HIV-1 infection and replication. In our previous studies we showed that CD63 silencing affects HIV-1 production in monocyte-derived MØ and a CD4+ cell line [25–27], and we now extend our investigations to study the role of CD63 in primary human peripheral blood lymphocytes (PBLs).
We sought to elucidate the effect of CD63 down regulation on viral production in PBLs. PBLs were transfected with CD63 siRNA or control siRNAs (ERBB2IP or CD4) for 48 h, followed by infection with HIV-189.6. HIV-1 production was assessed in culture supernatants by p24 ELISA at 7 days post-infection. As shown in Figure 2C, virus production in PBLs was significantly reduced following CD63 or CD4 silencing compared to ERBB2IP siRNA transfected cells (P < 0.05). Thus, our data strongly suggest that CD63 expression supports HIV-1 replication in PBLs.
Previously, we have shown that CD63 silencing significantly inhibits HIV-1 replication in MØ [25, 27], U1/HIV-1 producing cells , U373 CD4+ cell line , and presently in T lymphocytes (Figure 2C), revealing that CD63 expression is broadly required for replication in relevant HIV-1 target cells.
We further demonstrate dual roles for CD63, showing that it contributes to both early and late events of the HIV-1 replication cycle. CD63 mediated efficient entry of HIV-1 Env pseudotyped viruses into CCR5+ MØ (Figure 1). When viral entry was redirected though the endocytic pathway by pseudotyping virions with MLV or VSV, infectivity in MØ was not affected by CD63 silencing. However, CD63 silencing did reduce infectivity with R5- and R5X4-tropic viral pseudotypes that depend on CD4 and CCR5 for entry. This indicates (i) that CD63 supports Env-mediated entry or fusion events facilitated though CD4 and CCR5, and (ii) that the entry events are specific for the HIV-1 Env protein. In support, other investigators have demonstrated that the extracellular domain 2 of CD63 partially colocalizes with CD4 at the cell surface of macrophages .
CD63 also exerts a role in later stages of the HIV-1 replication cycle. As CD63 is a major component of late endosomes, it is possible that CD63 is also involved in HIV-1 maturation and budding in MØ. In this study, we show that silencing CD63 expression decreases extracellular, but not intracellular, HIV-1 p24 production (Figure 3A, B), indicating that CD63 may influence viral egress. In MØ, nascent HIV-1 virions accumulate and assemble in multi-vesicular bodies (MVBs) or endosomes containing tetraspanins such as CD63 and CD81, and may be released subsequently as exosomes. However, in T-cells HIV-1 Gag assembly is localized to the plasma membrane  where CD63 is also found. As CD63 is located in endosomes and the plasma membrane where HIV assembly takes place, it is possibly involved in virus assembly at these sites. This complex localization pattern of CD63 suggests that its intracellular trafficking and distribution must be tightly regulated.
Several studies have shown that CD63 supports HIV-1 replication [25–27], is located at assembly initiation sites [36–38], and is incorporated into nascent virions [15, 16], yet viral binding partners with CD63 have remained elusive. Exactly how CD63 is targeted to viral assembly sites and incorporated into budding HIV-1 particles also remains unclear. A plausible explanation is that virus budding may occur in TEMs and that CD63 must be present for the completion of the recycling loop with return of both CD63 and viral proteins to a common site for virus release. CD63-containing TEMs may be required for budding of virus from these cells.
In conclusion, we have shown that CD63 plays a role both in the early entry stages of the HIV-1 replication cycle in concert with CD4 and/or CCR5, and in a late replicative step, possibly at the level of egress. Further research is needed to gain insight into the molecular mechanisms of CD63 that facilitate early and late events in the HIV-1 replication cycle.
Primary monocyte-derived macrophages (MØ) and peripheral blood lymphocytes (PBLs) were isolated and purified from buffy coats of healthy HIV-negative blood donors prepared by the UTMB Blood Bank (Galveston, TX). Monocyte-derived MØ were prepared by Ficoll-Hypaque gradient centrifugation followed by adherence for 7 days to plastic petri dishes. During differentiation, MØ were cultured in Iscove’s modified Dulbecco’s medium (IMDM)  supplemented with 20% FCS; 1% L-glutamine and 1% Penicillin/Streptomycin as described in . Nonadherent cells (PBLs) were treated with phytohemagglutinin (PHA) for 72 h 37°C with 5% CO2 prior to propagation in RPMI 1640 supplemented with 20% fetal calf serum (FCS), 20 units/ml IL-2, 1% Penicillin/Streptomycin.
Our experimental research has been approved by the Institutional Biosafety Committee (IBC) at the University of Texas Medical Branch, Galveston, Texas. The IBC reference numbers are 2013040 (for use of HIV) and 2012033 (for use of primary cells and cell lines). There is no use of animals or humans in our studies.
U1/HIV-1 cells  (1 × 106) obtained from the NIH AIDS Research and Reference Reagent Program were plated in 24-well microtiter plates on day 1. Complete cell media (RPMI 1640 containing 2.0 mM L-glutamine; 10% heat-inactivated fetal bovine serum) was changed after 24 h. Forty-eight hours post-transfection (day 3), complete RPMI media plus phorbol 12-myristate 13-acetate (PMA) was added to cells. Intracellular and extracellular virus was measured in the cells lysates and culture supernatant on day 5 by p24 ELISA.
Dual-tropic (R5/X4) HIV-189.6 is an HIV-1 laboratory adapted strain originally isolated from an infected individual. The original preparation was prepared from molecularly cloned virus, and grown in CEMx174 cells  and donated to the NIH AIDS Research and Reference Reagent Program. We purchased HIV-189.6 from the Virology Core Facility, Center for AIDS Research at Baylor College of Medicine, Houston, TX, which was prepared and propagated in human PBMCs. HIV-189.6 stock containing 49.977 ng/ml of HIV p24 with 261,300 TCID50/ml was used to infect PBLs at an m.o.i of 0.02.
siRNAs targeting CD63, CD4, ERBB2IP, and TSG101-specific were designed and synthesized by Dharmacon (Lafayette, CO). The target sequences for siGENOME SMARTpool siRNA of CD63 includes D-017256 (01-GAGAUAAGGUGAUGUCAGA; 02-AAGGAGAACUAUUGUCUUA; 03-GGAUUAAUUUCAACGAGAA; 04-GAUGGAGAAUUACCCGAAA). The target sequences for siGENOME SMARTpool siRNA of CD4 includes D-005234 (01-GAACUGACCUGUACAGCUU; 02-AAUCAGGGCUCCUUCUUAA; 03-GAAGAAGAGCAUACAAUUC; 18-AUUACCAAGUGCCGGACUA); The target sequences for siGENOME SMARTpool siRNA of TSG101 includes M-003549 (01-AAACUGAGAUGGCGGAUGA; 02-GAACCUCACUGGAACAAUC; 04-CCGUUUAGAUCAAGAAGUA; 05-UCCCACAGCUCCCUUAUAC). The target sequences for siGENOME SMARTpool siRNA of ERBB2IP includes D-031861 (01-UGAAACAGCUCACAUAUUU; 02-UGUGAAAUCUCAUAGCAUA; 03-CGAAGAGCCAAAUAUAAUA; 04-CCAAACGACCGACUUAUUC). siRNAs transfections were performed using oligofectamine (Invitrogen, CA) or the Nucleofector™ Technology by Amaxa (Lonza, Switzerland) according to the manufacturers’ instructions. In brief, MØ adherent for 5 days were plated in 24-well plates (5 × 105 cells/well), and transfected with 50 nM siRNAs using oligofectamine in serum-free Opti-MEM I medium (Gibco) 24 h after plating. MØ were maintained in Iscove’s medium and 20% FCS after 4 h to terminate transfection. U1/HIV-1 cells were transfected with siRNA (200 nM final concentration) using Oligofectamine (Invitrogen) following the manufacturer’s instructions.
In order to measure down regulation of target genes in PBLs, cell lysates were prepared with cell lysis buffer (Promega, WI) at 2 days post-transfection, and were collected for Western blot analysis, or RNA was extracted for real time quantitative PCR analysis. PBLs were transfected with 50 nM siRNAs in 6-well plates (5 × 105 cells/well) using Nucleofector®, and standard applications of manufacture’s protocol (Amaxa) were followed. For Western blot analysis, anti-human CD63 monoclonal antibody (Santa Cruz) was used.
Forty eight hours post-transfection, PBLs were infected with HIV-189.6 (m.o.i. = 0.02). Culture supernatants were harvested for p24 detection on day 7 post-infection using a p24 Capture ELISA kit (ImmunoDiagnostics, Woburn, MA).
Pseudotype viruses containing the luciferase gene provide an efficient way to measure infection after CD4, CCR5, and CD63 down regulation. Stocks of single-round-infection of various viral Env pseudoviruses (MLV, VSV, HIV-1ADA, or HIV-189.6) were produced by cotransfecting 293 T cells (1.7 × 107 cells per T75 flask) with 2 μg of an HIV-1 rev/env expression plasmid and 12 μg of an env-deficient HIV-1 backbone plasmid (pNL4.3 ΔEnv) using Lipofectamine transfection reagent (Invitrogen). The NL4-3 proviral clone has a luciferase in place of nef (env - luc). Pseudovirus-containing supernatant was harvested 24 h following transfection and clarified by centrifugation and 0.45-μm filtration. Single-use aliquots (1.0 ml) were stored at −80°C. The 50% tissue culture infectious dose (TCID50) for each pseudovirus preparation was determined by infection of TZM-bl cells. These pseudovirus stocks then were used for transduction of MØs.
Total mRNA was isolated from siRNA-transfected cells and MØ using RNeasy Mini Kits (Qiagen). CD63 specific primers and probe were purchased from Applied Biosytems (Carlsbad, CA). All reactions were performed using Applied Biosystems TaqMan Universal Master Mix and run using an Applied Biosystems 7500 Fast Real Time PCR system and 7500 Fast System Software. Silencing of target genes was determined by normalizing target gene expression to GAPDH expression (n = 3).
The results are expressed as mean ± SD of at least four wells. Two-tailed, paired Student’s t-test was used to determine statistical significance. P values of <0.05*, and <0.01** were considered significant.
This work was supported by Public Health Service grant HL088999 from the National Heart, Lung, and Blood Institute. We thank the NIH AIDS Research and Reference Reagent Program for providing the U1/HIV-1 cells and various plasmids for generating pseudoviruses. We thank Edward Siwak, Ph.D., Associate Director of Virology Core Facility, Center for AIDS Research at Baylor College of Medicine, Houston, TX for providing HIV-189.6.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.